BR0318533A - azolidinacarbonitriles and their use as dpp-iv inhibitors - Google Patents

azolidinacarbonitriles and their use as dpp-iv inhibitors

Info

Publication number
BR0318533A
BR0318533A BRPI0318533-8A BR0318533A BR0318533A BR 0318533 A BR0318533 A BR 0318533A BR 0318533 A BR0318533 A BR 0318533A BR 0318533 A BR0318533 A BR 0318533A
Authority
BR
Brazil
Prior art keywords
compounds
treating
pharmaceutically acceptable
dpp
inhibitors
Prior art date
Application number
BRPI0318533-8A
Other languages
Portuguese (pt)
Inventor
Alangudi Sankaranarayanan
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR0318533A publication Critical patent/BR0318533A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)

Abstract

"AZOLIDINACARBONITRILAS E SEU USO COMO INIBIDORES DE DPP-IV". A invenção refere-se a novos compostos heterocíclicos, que se enquadram no âmbito da fórmula geral (I), seus estereoisómeros, sais e solvatos farmaceuticamente aceitáveis, em que X, n, k, z, R1, R2, R3, R4, R5 e R6 são conforme definidos no relatório descritivo, que são úteis na (i) normalização de elevados níveis de glicose no sangue em diabetes, (ii) tratar distúrbios relacionados à intolerância à glicose e (iii) para eliminar os radicais livres de mamíferos. A invenção também divulga composição farmaceuticamente aceitável que compreende esses compostos, método para preparação dos compostos conforme definidos acima e método para tratar mamíferos, inclusive seres humanos, pela administração de uma quantidade eficaz dos ditos compostos a um paciente, que necessite do mesmo. A invenção refere-se ainda ao uso desses compostos na fabricação de um medicamento útil para tratamento de diferentes condições de doenças, conforme estabelecido acima."AZOLIDINCARBONITRIES AND ITS USE AS DPP-IV INHIBITORS". The invention relates to novel heterocyclic compounds falling within the scope of general formula (I), their pharmaceutically acceptable stereoisomers, salts and solvates, wherein X, n, k, z, R 1, R 2, R 3, R 4, R 5 and R6 are as defined in the specification, which are useful in (i) normalizing high blood glucose levels in diabetes, (ii) treating glucose intolerance-related disorders and (iii) eliminating mammalian free radicals. The invention also discloses a pharmaceutically acceptable composition comprising such compounds, method for preparing the compounds as defined above and method for treating mammals, including humans, by administering an effective amount of said compounds to a patient in need thereof. The invention further relates to the use of such compounds in the manufacture of a medicament useful for treating different disease conditions as set forth above.

BRPI0318533-8A 2003-10-06 2003-10-06 azolidinacarbonitriles and their use as dpp-iv inhibitors BR0318533A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/004377 WO2005033106A1 (en) 2003-10-06 2003-10-06 Azolidinecarbonitriles and their use as dpp-iv inhibitors

Publications (1)

Publication Number Publication Date
BR0318533A true BR0318533A (en) 2006-09-12

Family

ID=34401253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318533-8A BR0318533A (en) 2003-10-06 2003-10-06 azolidinacarbonitriles and their use as dpp-iv inhibitors

Country Status (8)

Country Link
EP (1) EP1682540A1 (en)
JP (1) JP2007516154A (en)
CN (1) CN1839131A (en)
AU (1) AU2003269307A1 (en)
BR (1) BR0318533A (en)
CA (1) CA2534634A1 (en)
PL (1) PL380189A3 (en)
WO (1) WO2005033106A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
KR101790806B1 (en) 2010-03-10 2017-11-20 프로비오드룩 아게 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1682540A1 (en) 2006-07-26
CA2534634A1 (en) 2005-04-14
AU2003269307A1 (en) 2005-04-21
PL380189A3 (en) 2007-01-08
WO2005033106A1 (en) 2005-04-14
CN1839131A (en) 2006-09-27
JP2007516154A (en) 2007-06-21

Similar Documents

Publication Publication Date Title
BR0308816A (en) Thiazolidine-4-carbonitriles and analogs and their uses as dipeptide peptide inhibitors
BRPI0211665B8 (en) "substituted pyrrole compound"
BR0113039A (en) Compound or a physiologically acceptable salt or solvate thereof, use thereof, pharmaceutical composition, aerosol pharmaceutical formulation, method for treating a human or animal subject with an antiinflammatory and / or allergic condition, and process for preparing a compound
EA200500018A1 (en) BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION
BR0317435A (en) Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth
BRPI0412527A (en) compound, use thereof, pharmaceutical composition, aerosol pharmaceutical formulation, method for treating a human or animal patient with an anti-inflammatory and / or allergic condition, and process for preparing a compound.
BR0313160A (en) Compound, pharmaceutical composition, methods for treating a condition and a susceptible neoplasm in an animal in an animal, process for preparing a compound and use of a compound.
BRPI0614168A2 (en) COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, ISOFORM, TAUTOMER, OPTICAL ISOMER OR A COMBINATION THEREOF, PHARMACEUTICAL COMPOSITION, METHOD FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSCHIATRIC DISORDERS, USE OF A COMPOUND, AND, PROCESS FOR THE PREPARATION OF A COMPOUND
BR0115999A (en) A compound, a pharmaceutical composition comprising the same, its use, a process for the prophylactic or therapeutic treatment of type II diabetes, and a process for preparing the compound.
NO20064412L (en) Condensed heterocycle derivative, medical composition containing the same and medical use thereof
BRPI0515482A (en) heterocyclic derivatives and their uses as therapeutic agents
BRPI0416444B8 (en) heterocyclic boronic acid compound, pharmaceutical composition, and, pharmaceutical combination comprising the same
BRPI0208811B8 (en) pyrazole derivatives, their use and preparation process, as well as pharmaceutical composition comprising them
BR0212158A (en) Diarylcycloalkyl derivatives, processes for their preparation and their application as ppar activators
NO20070981L (en) Substituted oxazolidinones and their use in the field of blood coagulation.
BRPI0414514A (en) use of a compound, compound, and pharmaceutical compositions
BR0214986A (en) S-enanciomer of a compound, compound, pharmaceutical formulation, method of treating or preventing lipid disorders, use of a compound, method of treating or preventing type 2 diabetes, process for preparing a compound, and, pharmaceutical composition
BR9811055A (en) Compound, use of it, pharmaceutical composition, and process for treating disease or medical condition mediated by factor xa
AR045040A1 (en) DERIVATIVES OF SPIROAZABICICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES
BRPI0412997A (en) substituted thiazole benzoisothiazole dioxide derivatives, method for producing them and their use
BR9910179A (en) Compound, pharmaceutical composition, use of a compound, and process for treating a disease or condition mediated by factor xa in a warm-blooded animal
AR008387A1 (en) NEW 5-PHENOXIALKYL-THIAZOLIDIN-2,4-DIONES, PROCEDURES FOR OBTAINING THEM, NEW INTERMEDIATE COMPOUNDS OF THESE PROCEDURES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE NEW 5-PHENOXIALKYL-TIAZOLIDIN- 2,4-DIAZES
BRPI0407253A (en) Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds
BRPI0408767B8 (en) Non-nucleoside reverse transcriptase inhibitors for treatment of hiv-mediated diseases, their use, and pharmaceutical composition
BR0318533A (en) azolidinacarbonitriles and their use as dpp-iv inhibitors

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A,5A, 6A E 7A ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.